pipette
ESEspañol

Pediatric Influenza Vaccine Effectiveness Against Emergency Visits and Hospitalization in Canada: 2024-2025 and 2025-2026 seasons

J. C. Kwong, D. M. Goldfarb, M. Bhatt, J. Xie, S. A. Buchan, J. Papenburg, J. Cheng, M. Eltorki, Y. Finkelstein, V. Sabhaney, J. M. Pernica, J. Gravel, A. Kam, S. Berthelot, B. Burstein, J. Emsley, A. Mater, S. Ali, A. Shah, N. Poonai, D. Beer, P. Gill, J. Dickinson, S. Freedman

PreprintReal-world use

In the authors' words

Importance: Influenza causes substantial morbidity in children, yet Canadian data on influenza vaccine effectiveness (VE) in preventing emergency department (ED) visits and hospitalizations are limited. Objective: To estimate VE against influenza-associated ED visits and hospitalizations among children during the 2024-2025 and 2025-2026 seasons. Design: Test negative case control design. Setting: Fourteen Canadian pediatric tertiary-care hospitals participating in the Surveillance Program for the Rapid IdeNtification and TracKing of Infectious Diseases in kidS (SPRINT KIDS) network. Participants: Symptomatic children aged 6 months to <18 years tested for influenza from October 27, 2024, to June 7, 2025, and from November 2, 2025, to June 13, 2026. Exposure: At least one dose of current season influenza vaccine. Main Outcomes and Measures: VE against laboratory confirmed influenza A or B associated with an ED visit or hospitalization. VE was estimated using multivariable logistic regression adjusted for age, epidemiologic week, site, and high-risk comorbidity. Results: The 2024/2025 season included 17,316 encounters (median [IQR] age=41.0 [18.5, 82.3] months; 54.0% male), with 4,760 influenza-positive cases (8.9% vaccinated) and 12,556 influenza-negative controls (15.9% vaccinated). The 2025/2026 season included 13,417 encounters (median [IQR] age=33.5 [16.7, 74.8] months; 54.1% male), with 4,798 cases (7.6% vaccinated) and 8,619 controls (18.1% vaccinated). VE against any influenza was 47% (95%CI, 40%, 53%) and 53% (95%CI, 46%, 59%) in 2024/2025 and 2025/2026, respectively. VE against ED visits was 53% (95%CI, 45%, 59%) and 57% (95%CI, 49%, 63%), and VE against hospitalization was 33% (95%CI, 16%, 47%) and 48% (95%CI, 33%, 59%) in 2024/2025 and 2025/2026, respectively. VE was lower against influenza A as compared to B in both seasons: 31% (95%CI, 22%, 39%) vs. 75% (95%CI, 64%, 82%) (p<0.001) in 2024-2025; and 42% (95%CI, 32%, 50%) vs. 64% (95%CI, 55%, 72%) (p=0.001) in 2025/2026. VE was lower in children aged 10 to <18 years than in those <10 years, particularly among children with comorbidities. Protection against influenza A lasted up to 90 days, whereas it persisted beyond 120 days for influenza B. Conclusions and Relevance: Influenza vaccines were moderately effective against pediatric ED visits and hospitalizations in both seasons. Routine vaccination should continue to be recommended to prevent hospital-attended influenza.

Main resultThe abstract does not state a limitation.

Appeared: Thursday, November 5. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.03.26367131